Article Text
PDF
Statistics from Altmetric.com
Gebhardt draws attention to an important issue. The responsibility for informing and warning patients about adverse effects and how to prevent them, or to recognise them early and minimise harm, is shared between the manufacturer, the national regulatory agency, the prescriber, and the pharmacist. The first two must ensure that prescribers and pharmacists are adequately equipped and helped to do their part. Any printed information needs to be tested on a sample of actual patients to demonstrate that over 90% can actually understand and use it. Beyond that, doctors and pharmacist have to be motivated and helped to check (and document in their records) how well the individual patient has understood the problems and the information.
Other content recommended for you
- Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity
- Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study
- Monitoring, reporting and regulating medicine quality: tensions between theory and practice in Tanzania
- Spurious and counterfeit drugs: a growing industry in the developing world
- Evaluation of the decision-making process underlying the initial off-label use of vaccines: a scoping review protocol
- Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons and possible solutions to overcome the barriers
- Unlicensed and off label drug use in paediatric wards: prospective study
- Unlicensed and off label drug use in neonates
- Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
- Unlicensed and off label prescribing of drugs in general practice